Who is sponsoring NCT06611137?

NCT06611137 is sponsored by Sun Yat-sen University.

What drugs are being tested in NCT06611137?

Interventions in NCT06611137: SBRT+Toripalimab Plus Docetaxel and Cisplatin.

What condition does NCT06611137 study?

NCT06611137 studies Laryngeal Cancer, Hypopharynx Cancer.

Is NCT06611137 still recruiting?

NCT06611137 is currently recruiting now. Last updated 26 September 2024.

Last reviewed 2024-09-26 · How we verify

NCT06611137

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SBRT Followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Larynx Preservation in Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx

Recruiting now Phase 2 Last updated 26 September 2024

What this trial tests

Phase 2 trial testing SBRT+Toripalimab Plus Docetaxel and Cisplatin in Laryngeal Cancer in 35 participants. Currently enrolling.

Timeline

11 September 2024

Primary endpoint
11 September 2025

11 September 2027

Quick facts

Lead sponsor	Sun Yat-sen University
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	35
Start date	11 September 2024
Primary completion	11 September 2025
Estimated completion	11 September 2027
Sites	1 location across China

Drugs / interventions tested

SBRT+Toripalimab Plus Docetaxel and Cisplatin

Conditions studied

Laryngeal Cancer — all drugs for Laryngeal Cancer →
Hypopharynx Cancer — all drugs for Hypopharynx Cancer →

Sponsor

Sun Yat-sen University

Who can join

Adults 18 to 70, any sex, with Laryngeal Cancer or Hypopharynx Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial aims to evaluate the safety and efficiency of SBRT followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Systemic therapy for laryngeal carcinoma.
Fuereder T, Kocher F, Vermorken JB. · · 2025 · cited 4× · PMID 40104492 · DOI 10.3389/fonc.2025.1541385

Verify or expand the search:

Other recruiting trials for Laryngeal Cancer

Currently open trials in the same condition.

NCT07209189 — Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-esca · Phase 2 · recruiting
NCT06761937 — Thermoradiotherapy for Locally Advanced Head and Neck Cancer Patients · Phase 1 · recruiting
NCT06077643 — Workshops and Exchange Groups for Laryngectomized Patients · recruiting
NCT05894070 — The Voice as a Tool to Detect Recurrence of Laryngeal and Hypopharyngeal Cancer · recruiting
NCT05375266 — Immune Biomarker Study for Head and Neck Cancer · recruiting

Other Sun Yat-sen University trials

Trials by the same sponsor.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06611137 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
Last refreshed: 26 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06611137.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing